Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation

被引:30
作者
Atra, A [1 ]
Millar, B [1 ]
Shepherd, V [1 ]
Shankar, A [1 ]
Wilson, K [1 ]
Treleaven, J [1 ]
PritchardJones, K [1 ]
Meller, ST [1 ]
Pinkerton, CR [1 ]
机构
[1] ROYAL MARSDEN HOSP NHS TRUST,DEPT PAEDIAT ONCOL,DEPT HAEMATOL,SUTTON SM2 5PT,SURREY,ENGLAND
关键词
donor lymphocyte infusion; acute lymphoblastic leukaemia; childhood; bone marrow transplantation; graft-versus-host disease;
D O I
10.1046/j.1365-2141.1997.62650.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Four children with acute lymphoblastic leukaemia (ALL) who relapsed after allogeneic bone marrow transplantation (BMT) were treated with donor lymphocyte infusion (DLI) without prior conditioning. Three patients had previously received a non-T-cell-depleted matched sibling BMT and the fourth had a T-cell-depleted matched unrelated BMT. Two patients developed grade III-IV acute graft-versus-host-disease (GVHD) of the skin, which required intervention. Both are alive in complete haematological remission 7 and 10 months from DLI with chronic GVHD of the skin requiring immunosuppressive therapy. A third patient went into haematological remission 6 weeks after DLI, but with no clinical evidence of GVHD. His bone marrow remained in remission 11 months post-DLI despite the disease (ALL) relapsing in extramedullary sites. The fourth patient showed no clinical or haematological response to three consecutive doses of DLI given at 4-weekly intervals and died from progressive disease 11 months after relapse. These preliminary observations indicate that in constrast to experience in adult ALL, DLI may be effective in inducing sustained remission in children with ALL relapsing after BMT, and a response may occur even in the absence of clinical evidence of GVHD.
引用
收藏
页码:165 / 168
页数:4
相关论文
共 12 条
[1]  
BARRETT AJ, 1989, BLOOD, V74, P862
[2]   2ND TRANSPLANTS FOR LEUKEMIC RELAPSE AFTER BONE-MARROW TRANSPLANTATION - HIGH EARLY MORTALITY BUT FAVORABLE EFFECT OF CHRONIC GVHD ON CONTINUED REMISSION - A REPORT BY THE EBMT-LEUKEMIA-WORKING-PARTY [J].
BARRETT, AJ ;
LOCATELLI, F ;
TRELEAVEN, JG ;
GRATWOHL, A ;
SZYDLO, R ;
ZWAAN, FE .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (04) :567-574
[3]   SUCCESSFUL REINDUCTION OF PATIENTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA WHO RELAPSE FOLLOWING BONE-MARROW TRANSPLANTATION [J].
BOSTROM, B ;
WOODS, WG ;
NESBIT, ME ;
KRIVIT, W ;
KERSEY, J ;
WEISDORF, D ;
HAAKE, R ;
GOLDMAN, AI ;
RAMSAY, NKC .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) :376-381
[4]  
CHASTY RC, 1993, BONE MARROW TRANSPL, V12, P331
[5]   Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia [J].
Glass, B ;
Uharek, L ;
Zeis, M ;
Loeffler, H ;
MuellerRuchholtz, W ;
Gassmann, W .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (02) :412-420
[6]   DONOR LEUKOCYTE TRANSFUSIONS FOR TREATMENT OF RECURRENT CHRONIC MYELOGENOUS LEUKEMIA IN MARROW TRANSPLANT PATIENTS [J].
KOLB, HJ ;
MITTERMULLER, J ;
CLEMM, C ;
HOLLER, E ;
LEDDEROSE, G ;
BREHM, G ;
HEIM, M ;
WILMANNS, W .
BLOOD, 1990, 76 (12) :2462-2465
[7]  
KOLB HJ, 1995, BLOOD, V86, P20441
[8]   LEUKEMIA - MANAGEMENT OF RELAPSE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
KUMAR, L .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1710-1717
[9]  
MARAMONT AM, 1991, BLOOD, V78, P2120
[10]  
MRSIC M, 1992, BONE MARROW TRANSPL, V9, P269